{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:18:17Z","timestamp":1789561097094,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1248,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Minimal hepatic encephalopathy (MHE) in cirrhosis is associated with impaired driving skills and increased risk of motor vehicle accidents (MVAs). Detection and treatment of MHE has the potential to reduce costs and morbidity associated with MVAs. We conducted a cost-effectiveness analysis to assess the benefits of different strategies of MHE diagnosis and treatment for reducing MVA-related societal costs. The analyses compared five MHE management strategies: (1) presumptive treatment of all cirrhosis patients; (2) diagnosis by neuropsychological exam (NPE) with treatment; (3) diagnosis by standard psychometric tests (SPTs) with treatment; (4) diagnosis by rapid screening using inhibitory control test (ICT) with treatment; and (5) no MHE diagnosis or treatment (status quo). Treatments considered were lactulose or rifaximin, which were assumed to reduce the MVA rate to the level of similarly aged noncirrhosis patients with benefit adjusted for treatment compliance. A Markov model followed a simulated cohort of 1,000 cirrhosis patients without overt hepatic encephalopathy (OHE), from entry into treatment, through MHE development, and later OHE, when they exited the modeled cohort. Follow-up was for 5 years and included biannual MHE testing. The societal cost of a single MVA was estimated at $42,100. All four strategies with lactulose were cost-saving compared with the status quo. Diagnosis with ICT and lactulose was the most cost-effective approach (cost\/MVA prevented: $24,454 ICT; $25,470 SPT; $30,469 presumptive treatment and $33,742 NPE). Net program savings over 5 years ranged from $1.7 to 3.6 million depending on the strategy. Rifaximin therapy was not cost-saving at current prices but would become so at a monthly cost of &lt;$353.\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                      Detection of MHE, especially using the ICT, and subsequent treatment with lactulose could substantially reduce societal costs by preventing MVAs. (Hepatology 2012)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.25507","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T01:08:17Z","timestamp":1322874497000},"page":"1164-1171","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":114,"title":["Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis"],"prefix":"10.1097","volume":"55","author":[{"given":"Jasmohan S.","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pinkerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Heuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20241201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathydefinition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.","volume":"35","author":"Ferenci","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-20-20241201","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1440-1746.2001.02487.x","article-title":"Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.","volume":"16","author":"Das","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20-20241201","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2007.02.022","article-title":"Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy.","volume":"47","author":"Sharma","year":"2007","journal-title":"J Hepatol"},{"key":"R4-20-20241201","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0168-8278(86)80149-0","article-title":"The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, nonshunted patients with cirrhosis.","volume":"3","author":"Gitlin","year":"1986","journal-title":"J Hepatol"},{"key":"R5-20-20241201","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2001.04130.x","article-title":"Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.","volume":"96","author":"RomeroGomez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R6-20-20241201","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1111\/j.1572-0241.2007.01424.x","article-title":"Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations.","volume":"102","author":"Bajaj","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R7-20-20241201","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.20095","article-title":"Minimal hepatic encephalopathy impairs fitness to drive.","volume":"39","author":"Wein","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R8-20-20241201","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02081029","article-title":"Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.","volume":"10","author":"Watanabe","year":"1995","journal-title":"Metab Brain Dis"},{"key":"R9-20-20241201","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hep.22032","article-title":"Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy.","volume":"47","author":"Bajaj","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R10-20-20241201","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1023\/A:1005556826152","article-title":"Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.","volume":"45","author":"Dhiman","year":"2000","journal-title":"Dig Dis Sci"},{"key":"R12-20-20241201","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathyan International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.","volume":"33","author":"Bajaj","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20-20241201","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-2007-984576","article-title":"An algorithm for the management of hepatic encephalopathy.","volume":"27","author":"Mullen","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R14-20-20241201","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.21515","article-title":"Testing for minimal hepatic encephalopathy in the United States: an AASLD survey.","volume":"45","author":"Bajaj","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R17-20-20241201","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test.","volume":"50","author":"Bajaj","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R18-20-20241201","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajg.2011.04.002","article-title":"Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis.","volume":"12","author":"Gad","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"R19-20-20241201","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.puhe.2008.06.009","article-title":"Road traffic injuries: a major global public health crisis.","volume":"122","author":"Sharma","year":"2008","journal-title":"Public Health"},{"key":"R21-20-20241201","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and healthrelated quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.","volume":"45","author":"Prasad","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R22-20-20241201","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/hep.510260606","article-title":"Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.","volume":"26","author":"Watanabe","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R23-20-20241201","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2036.1997.118289000.x","article-title":"Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.","volume":"11","author":"Horsmans","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20-20241201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and healthrelated quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R26-20-20241201","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.23866","article-title":"Drug therapy: rifaximin.","volume":"52","author":"Bajaj","year":"2011","journal-title":"HEPATOLOGY"},{"key":"R28-20-20241201","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","article-title":"The costeffectiveness and budget impact of competing therapies in hepatic encephalopathy a decision analysis.","volume":"26","author":"Huang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-20-20241201","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0016-5085(78)90851-X","article-title":"Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.","volume":"75","author":"Rikkers","year":"1978","journal-title":"Gastroenterology"},{"key":"R30-20-20241201","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cgh.2010.10.002","article-title":"Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy.","volume":"9","author":"Riggio","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-20-20241201","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1080\/00365520600825117","article-title":"Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and healthrelated quality of life.","volume":"41","author":"Kalaitzakis","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"R34-20-20241201","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1365-2036.2010.04257.x","article-title":"Predictors of the recurrence of hepatic encephalopathy in lactulosetreated patients.","volume":"31","author":"Bajaj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-20-20241201","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0168-8278(01)00026-5","article-title":"Neuropsychological characterization of hepatic encephalopathy.","volume":"34","author":"Weissenborn","year":"2001","journal-title":"J Hepatol"},{"key":"R36-20-20241201","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1053\/j.gastro.2008.09.040","article-title":"The demise of the pencil? New computerassisted tests for minimal hepatic encephalopathy.","volume":"135","author":"Iduru","year":"2008","journal-title":"Gastroenterology"},{"key":"R40-20-20241201","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25507","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201204000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:35:10Z","timestamp":1733042110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201204000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25507","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717548013.793003015","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}